Form 12b-25.--NOTIFICATION OF LATE FILING
FORM 12b-25
SEC FILE NUMBER
0-26126
-------
CUSIP NUMBER
817523 10 3
-----------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
(Check One). Form 10-K Form 20-F Form 11-K X Form 10 Q Form N-SAR
-- -- -- -- --
For Period Ended: September 26,1999
-----------------
/ / Transition Report on Form 10-K
/ / Transition Report on Form 20-F
/ / Transition Report on Form 11-K
/ / Transition Report on Form 10-Q
/ / Transition Report on Form N-SAR
For the Transition Period Ended:
-----------------------------------------
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:
PART I--REGISTRANT INFORMATION
Serologicals Corporation
- ---------------------------------------------------------------------------
Full Name of Registrant
Serologicals Holdings, Inc.
- ---------------------------------------------------------------------------
Former Name if Applicable
780 Park North Blvd., Suite 110
- ---------------------------------------------------------------------------
Address Principal Executive Office (Street and Number)
Clarkston, Georgia 30021
- ---------------------------------------------------------------------------
City State and Zip Code
PART II--Rules 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
/X/ (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
<PAGE>
/X/ (b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be
filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report of transition
report on Form 10-Q, or portion thereof will be filed on or before
the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-
25(c) has been attached if applicable.
PART III--NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period. (Attach Extra Sheets if Needed)
As a result of unexpected delays in obtaining certain financial data
resulting from turnover of several positions in the accounting department,
the report on Form 10-Q could not be timely filed without unreasonable effort
or expense.
PART IV-OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Peter J. Pizzo, III 404 296-5595
--------------------------- ----------- ----------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter
period that the registrant was required to file such report(s) been
filed? If answer is no, identify report(s). X Yes No
--- ---
- -----------------------------------------------------------------------------
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statement to be included in the subject report or portion
thereof? X Yes No
--- ---
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
The Company previously announced that it will be reporting a net loss and
net income for the three and nine months ended September 26, 1999 of
($5,985,000) and $1,376,000, respectively, versus net income for the three
and nine months ended September 27, 1998, of $4,098,000 and $12,019,000,
respectively. The results for the three and nine months were impacted by
shipping delays affecting approximately $19 million of sales and special
charges of $8,575,000.
- -----------------------------------------------------------------------------
SEROLOGICALS CORPORATION
--------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date November 12, 1999
------------------
By /s/Peter J. Pizzo, III
----------------------
Chief Financial Officer
INSTRUCTION: The form may be signed by an executive officer of the registrant
or by any other duly authorized representative. The name and title of the
person signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).
<PAGE>
